Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11670635 | 0.84 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL21177760 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL27666403 | 0.80 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL30788376 | 0.80 | ESR1 (0.46) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL73498 | 0.80 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL28848601 | 0.80 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL18428498 | 0.80 | ESR1 (0.46) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL11141219 | 0.78 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL1625604 | 0.78 | FDPS (0.52) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL1068241 | 0.78 | ESR1 (0.70) | SLC6A4SLC6A2SLC6A3LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-4474748-A | ANTIBIOTICS, FUNGICIDES, ANTISEPTICS | JOHNSON & JOHNSON (US) | 1984-10-02 | — | — | US | claimed |
| JP-58096002-A | — | — | None | — | — | JP | disclosed |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| WO-2022076507-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-107501241-B | Compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative diseases | 梅制药公司 | 2020-10-13 | — | — | CN | disclosed |
| EP-0201365-A1 | Process for the electrosynthesis of alcohols and epoxide compounds | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1986-11-12 | — | — | EP | disclosed |
| US-4474748-A | ANTIBIOTICS, FUNGICIDES, ANTISEPTICS | JOHNSON & JOHNSON (US) | 1984-10-02 | — | — | US | disclosed |
| JP-S5896002-A | INSECT PEST REPELLING COMPOSITION AND INSECT PEST REPELLENT | EARTH CHEM CORP LTD | 1983-06-07 | — | — | JP | disclosed |
| US-4331684-A | ARALKYL ESTERS OF AMINO ACIDS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1982-05-25 | — | — | US | disclosed |
| US-4321257-A | Potentiated medicaments | JOHNSON & JOHNSON (US) | 1982-03-23 | — | — | US | disclosed |
| US-4237311-A | ANTIDEPRESSANTS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1980-12-02 | — | — | US | disclosed |
| US-4197318-A | CYCLOHEXYL SUBSTITUTED ALKANOLS AS POTENTIATORS | JOHNSON & JOHNSON (US) | 1980-04-08 | — | — | US | disclosed |
| US-4091090-A | PENETRANT ACCELERATOR COMPRISING CYCLOHEXYL-SUBSTITUTED ALKANOLS | JOHNSON & JOHNSON (US) | 1978-05-23 | — | — | US | disclosed |
| US-4006218-A | MICROBIOCIDE | JOHNSON & JOHNSON (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | SLC6A4 4601/4885SLC6A2 4508/4885SLC6A3 4590/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | SLC6A4 4601/4885SLC6A2 4508/4885SLC6A3 4590/4885 |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | SLC6A4 4601/4885SLC6A2 4508/4885SLC6A3 4590/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | SLC6A4 4235/4885SLC6A2 3591/4885SLC6A3 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.